Alex Bachmann is the Chief of the Department of Urology, University Hospital Basel, Switzerland. He is specialized in ablative and reconstructive laparoscopic surgery. Having used the Greenlight laser since the very first time in 2002, he is an expert of laser prostatectomy, Executive Member of EAU working group BPH and Executive Board Member of German Working Group of Endourology, Laparoscopy and Robotics. He is a founding Member of International Greenlight User Group (IGLU) and has published over 90 scientific publications, including 12 book chapters. He was invited at numerous international meetings with live surgery / presentations / workshops / congresses and teaching events in Germany, India, Spain, UK, US, Slovenia, Austria, South Africa, Tanzania, Senegal, Australia.

Christopher R Chapple trained at the Middlesex Hospital where he subsequently completed his doctorate. He is a Consultant Urological Surgeon at Sheffield Teaching Hospitals and visiting professor at Sheffield Hallam University. He has a particular interest in Functional Reconstruction of the Lower Urinary Tract and the underlying Pharmacological Control Mechanisms. He is Past Director of the European School of Urology and an Adjunct Secretary General to the European Association of Urology responsible for education . He is editor of the journal Neurourology and Urodynamics and is on the editorial board of several journals. He has co-authored over 300 articles in peer-reviewed Journals and has written several books and a number of book chapters. He has chaired a number of guidelines initiatives including the recent UK Male LUTS guidelines report for NICE.

John M Fitzpatrick is Editor-in-Chief of BJUI and is on the editorial board of 25 other Journals. He is Professor and Chairman of the Department of Surgery in the Mater Misericordiae Hospital and University College Dublin. He is Past President of the British Association of Urological Surgeons and of the Irish Society of Urology. He is a member of the Board of Trustees of The British Urological Foundation and was Chairman of the Scientific Committee of that Foundation. He is an Honorary Fellow of the College of Urologists of South Africa and an Honorary member of the British Association of Urological Surgeons and of the American Urological Association as well as an Honorary member of the Urological Societies of Australasia, South Africa, Germany, Netherlands, India, Hungary, Argentina, Greece, and Georgia. Professor Fitzpatrick has performed over 90 visiting professorships in the United States and other countries throughout the world. He has also given over 300 guest lectures throughout the world. He has published widely and is editor of seventeen text books.

Stephen J Freedland is a Urologist within the Duke Prostate Center at Duke University.  He is an Associate Professor of Surgery (Urology) and Pathology.  He also holds an appointment at the Durham VA Hospital.  He is the Vice Chief of Research in the Division of Urological Surgery and the Director of Clinical Research for the Genitourinary Cancer Program within the Duke Cancer Institute. He specializes in the diagnosis, treatment, and long-term management of prostate cancer patients. He has extensive research interests in risk stratification, the role of obesity and nutrition in prostate cancer, and the role of and side effects from hormonal therapy. He completed his undergraduate at UCLA and then medical school at UC Davis.  Following this, he completed his residency in Urology at UCLA and a urological oncology fellowship at Johns Hopkins.  He currently runs an active research program with funding from the National Cancer Institute, the Department of Defense, and the Prostate Cancer Foundation.

David Gillatt is the Medical Director of the Bristol Urological Institute (BUI) and one of UK’s leading urological cancer surgeons. He established the BUI’s Prostate Cancer Care and Research Centre and his interests include discovery and optimisation of biomarkers for early prostate cancer diagnosis and prognosis, and the effect of ketamine abuse on bladder function.

Sender Herschorn MD, is Professor and Chair of the Division of Urology at the University of Toronto and attending Urologist and Head of Urodynamics Laboratory at Sunnybrook Health Sciences Centre. He holds the Martin Barkin Chair in Urological Research, the first University Chair in Urology. Dr. Herschorn has been a senior investigator in clinical trials relating to urinary incontinence, overactive bladder, and erectile dysfunction. He has been the recipient of many honours and awards including being cited in “The Best Doctors in America” (1992-1993 and 1994-1995 for work in Neurourology and voiding dysfunction) and cited in “Best Doctors in Canada” in 2002 – 2003. He has won undergraduate, postgraduate, and continuing education awards at the University of Toronto as well as the Zimskind Award of the Society for Urodynamics and Female Urology.

Piet Hoebeke is head of the department of Urology at the University Hospital, Gent, Belgium, and is Senior full Professor of Paediatric Urology. He is a member of the board of directors of the Ghent University Hospital. He received his initial medical training at the University of Gent, and then trained as a paediatric urologist at Utrecht University, the Netherlands. Dr Hoebeke’s special fields of interest are incontinence in children and urogenital reconstruction in children, adolescents and adults. He is a member of three multi-disciplinary teams – paediatric urology and nephrology; disorders of sex development and gender dysphoria at Gent University Hospital, and is involved in urogenital reconstruction and transsexual surgery. He is a member of various professional associations including the Belgian Society of Urology and the European Association of Urology. He is Fellow of the European Board of Urology and Fellow of the European Society of Paediatric Urology. Dr Hoebeke is a reviewer for five urology journals, has presented many papers at national and international meetings and has authored and co-authored more than 132 publications in peer-reviewed journals. He is board member of the ESPU and the ICCS. Is member of the editorial board of the European Journal of Urology and the journal of Urology and assistant editor of the Journal of Paediatric Urology.

Adrian Joyce is President of the British Association of Urological Surgeons (BAUS) from 2010 until 2012. Adrian has worked as a Consultant Urologist at St James’s University Hospital and Honorary Senior Lecturer at the University of Leeds, since 1992 with specific subspecialty interests in Endourology, Upper Tract Minimally Invasive Surgery including Laparoscopy and male factor infertility. Adrian has a particular focus on teaching the fundamentals of Endourology and laparoscopy with a regular commitment to skills teaching both nationally and internationally. Adrian's research interests include the management and research of Urolithiasis and Renal Cell Cancer, with over 60 publications in peer-reviewed journals.

Roger Kirby is the UK’s best known and most experienced prostate surgeon, with an international reputation as a clinician, researcher, communicator and writer. Always in the vanguard of advances in patient care, he has performed nearly 2000 radical prostatectomy operations (the last 800 using the da Vinci robot); written over 60 books and published more than 300 scientific papers; is founder of the journal Prostate Cancer and Prostatic Diseases; has been heavily involved in the development of national guidelines for prostate healthcare, and maintains his state-of-the-art expertise by attending scientific meetings and lecturing around the world. At the same time he has had a long-standing interest in the wider issues of men’s health and patient safety, on which he has launched a number of pioneering initiatives. He was Chairman of the charity Prostate UK until it became Prostate Action in 2010, and continues as a trustee; and is Secretary of The Urological Foundation. He has personally raised over £3 million through marathon running, mountain climbing, trekking and cycling challenges for both The Urology Foundation and Prostate UK.   

Dean Knoll MD is the Medical Director for both the Center for Urological Treatment and Medical Research Associates of Nashville in Nashville, Tennessee. Dr. Knoll received his medical degree from the University of Health Sciences, Chicago Medical School, North Chicago, Illinois. He completed an internship in general surgery and a residency in urology at the Mayo Clinic in Rochester, Minnesota. A frequent contributor to the medical press, Dr. Knoll has published over 100 peer-reviewed articles, abstracts and book chapters. He has delivered numerous lectures and operated both nationally and internationally.

Ji Youl Lee MD, PhD, is Professor and Director of the Urology Oncology Team at the St. Mary’s Hospital of the Catholic University of Korea in Seoul. He also holds an appointment as the secretary-general in Asian Pacific Prostate Society. He completed his Masters and Doctorate at the Catholic University.  Following this, he completed his residency in Urology at St. Mary's Hospital, CUMC and a Research fellowship in University of Pittsburgh Medical Center.  Currently, he successfully runs the Korea Prostate Bank established in 2006. It contains a nation-wide network of 16 hospitals in Korea and funded by government. It has also signed a memorandum of understanding (MOU) with major hospitals in USA, China, Japan, Taiwan and Singapore

James E Lingeman is a Professor of Urology at Indiana University School of Medicine.  He is well known nationally and internationally for his interest in the area of kidney stone disease and minimally invasive urologic techniques.  He is currently Director of the International Kidney Stone Institute.  Dr. Lingeman is Chairman of the Board of the Methodist Research Institute and a member of the Board of Directors of Indiana University Health, a healthcare system comprised of 18 hospitals in the State of Indiana.  He is past president of the Indiana State Urologic Society and past president of the North Central Section of the American Urological Association.  He is a member of the American Association of Genitourinary Surgeons (AAGUS).  Dr. Lingeman is the author of approximately 300 scientific publications. 

Anthony Mundy is the Professor of Urology in the University of London at Royal Free and University College London School of Medicine and Consultant Urological Surgeon at UCL Hospitals. He is also Honorary Civilian Consultant Urologist to the Royal Navy. He has been a past President of BAUS and a current council member of the Royal College of surgeons. He has a long and distinguished career in urological reconstruction. His hobbies include history and fine wines.
 

Christopher K Payne grew up in West Virginia and attended the University of Virginia where he received a BA degree in Chemistry with a minor in English.  He attended Vanderbilt University Medical School followed by urology residency at the University of Pennsylvania.  He subsequently completed a fellowship in Female Urology at UCLA.  He was recruited to Stanford University in August 1993 to initiate a new program in Female Urology and NeuroUrology where he currently serves as Professor of Urology. Dr. Payne is recognized as a leader on issues in female urology having served on NIH advisory/oversight panels on urinary incontinence and interstitial cystitis and his expertise in clinical research has been recognized through two NIH grants principal investigator grants focusing on treatment of interstitial cystitis.  He has served three times as the committee chair for “Research Methodology” for the International Consultation on Incontinence.  

David Quinn is currently the Medical Director of the Norris Cancer Hospital and Clinics, Leader of the Developmental Therapeutics Program for the Norris Comprehensive Cancer Center, Head, Section of Genitourinary Medical Oncology and Associate Professor of Medicine in the Division of Cancer Medicine and Blood Diseases, Keck School of Medicine, University of Southern California. He is a medical oncologist and an international expert in the field of clinical trials and molecular correlative studies in genitourinary cancer and early therapeutics.  He has been an invited speaker in more than 30 countries. His recent focus is on clinical trials and translation applications at USC and with SWOG and the California Cancer Consortium, where he has been principal investigator on clinical trials for locally advanced and castrate-resistant prostate cancer, high grade urothelial cancer, metastatic renal cell cancer and refractory germ cell tumours.

Monique J Roobol is associate professor and the head of the screening office of the Department of Urology at Erasmus Medical Centre Rotterdam, The Netherlands. She has a master and PhD degree in epidemiology. In the past she worked as a research technician in molecular biology. The screening office of the Department of Urology performs several clinical and population based screening studies. On average three to four PhD students are working under her guidance. She is responsible for the Dutch part of the European Randomized study of Screening for prostate cancer (www.erspc.org), the prostate cancer active surveillance project PRIAS (www.prias-project.org) and the Dutch bladder cancer screening trial (www.blu-project.org). She is a board member of the ERSPC Foundation and the Dutch Prostate Cancer research Foundation (SWOP) Next to this she is an active member of the Epidemiology committee of the ERSPC. Her main interest is in predictive modeling. Up to now Dr. Roobol has (co)-authored over 140 scientific publications, book chapters and reviews. Her research has been awarded with several prizes such as the bi-annual “van Stockum price” from the Dutch Urological Association for best thesis, the EAU best clinical paper of the year 2009 and the European Urology Platinum Award 2011. She is invited speaker at the major urological congresses such as AUA, EAU, ASCO GU and SIU. The media regularly cover her work. 

Anna Rosamilia graduated medicine from the University of Melbourne, and undertook Obstetrics and Gynaecology training at Monash Medical Centre, Melbourne and St. Mary’s Hospital, Manchester, UK. She undertook sub-specialist training at The Royal Women’s Hospital and Mercy Hospital for Women, Melbourne and holds a Sub-specialist Certificate of Urogynaecology (2000). In 2001, she received her Doctor of Philosophy from Monash University. She works as a Urogynaecologist at Monash Medical Centre and in private practice.

Steven W Siegel is the Director of the Continence Care Center of Metropolitan Urologic Specialists, PA, where he directs a fellowship program in female urology and voiding dysfunction. He plays an active role in clinical research and education about neuromodulation in urology. He is a Past President of the International Society of Pelvic Neuromodulation and the North Central Section of the American Urological Association, and current at Head of the Practice Standards Committee of the Society of Urodynamics and Female Urology.

Michael Wong is a Senior Consultant Urologist who is internationally recognized for his surgical expertise and academic contribution to the field of Urology, in particular the subspecialized field of minimally invasive Endourology and Female Urology. Currently, he is the Medical Director and Senior Consultant of the Urology, Fertility and Gynaecology Centre at the Mount Elizabeth Hospital, as well as President of Singapore Urological Association.